Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
(Reuters) - Japan's Astellas Pharma said on Monday it had fully acquired drugmaker IVERIC Bio Inc, through Berry Merger Sub, Inc, a wholly-owned subsidiary of Astellas US Holding, Inc.
Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,586 JPY | -0.50% | +4.38% | 1.83TCr | ||
39.95 USD | +0.38% | +1.09% | 551.22Cr | ||
2,757 PTS | +0.33% | +1.14% | - | ||